sponsored
PatientsVille.com Logo

PatientsVille

Qvar Medical Research Studies

Up-to-date List of Qvar Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Qvar Medical Research Studies

Rank Status Study
1 Recruiting A Study Evaluating the Effect of Inhaled and Nasal Corticosteroids on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis
Conditions: Asthma;   Allergic Rhinitis
Interventions: Drug: Alvesco/Omnaris, Qvar/Beconase, Placebo/Placebo;   Drug: Alvesco/Omnaris, Placebo/Placebo, Qvar/Beconase;   Drug: Qvar/Beconase, Alvesco/Omnaris, Placebo/Placebo;   Drug: Qvar/Beconase, Placebo/Placebo, Alvesco/Omnaris;   Drug: Placebo/Placebo, Alvesco/Omnaris, Qvar/Beconase;   Drug: Placebo/Placebo, Qvar/Beconase, Alvesco/Omnaris
Outcome Measures: The effect of Omnaris Nasal Spray & Alvesco Inhalation Aerosol vs Beconase AQ Nasal Spray & Qvar Inhalation Aerosol on short-term lower leg growth velocity as measured by knemometry in pediatric subjects w/ mild asthma & allergic rhinitis.;   The Effects of Omnaris, Alvesco, Beconase AQ and Qvar vs Placebo Nasal Spray & Placebo Inhalation Aerosol on short-term lower leg growth velocity as measured by knemometry in pediatric subjects w/ mild asthma & allergic rhinitis.
2 Not yet recruiting Effects of Qvar in Smokers With Asthma
Condition: Asthma
Interventions: Drug: Beclomethasone (Qvar);   Drug: Beclomethasone (Clenil);   Drug: Fluticasone
Outcome Measures: PD20 Adenosine;   Symptoms and Peakflow;   Airway resistance;   Spirometry;   Body Plethysmography;   Peripheral blood;   Delta FVC during PD20 small particle adenosine.;   Questionnaires;   Multiple Breath Washout Analysis;   Nasal brushing
3 Unknown  Inhaled Extra-fine Hydrofluoalkane-beclomethasone (Qvar) in Premature Infants With Bronchopulmonary Dysplasia (BPD)
Condition: Bronchopulmonary Dysplasia
Intervention: Drug: Inhaled extra-fine hydrofluoalkane-beclomethasone (Qvar)
Outcome Measures: The primary outcome will be to compare the rate of readmissions to the hospital for BPD exacerbation during the study period between infants treated with Qvar vs. placebo.;   Clinical outcomes at each visit
4 Recruiting Effect of Flovent Discus vs Qvar vs Pulmicort Flexhaler on Short Term Growth
Condition: Asthma
Interventions: Drug: Fluticasone, Budesonide, Beclomethasone;   Drug: Fluticasone, Beclomethasone, Budesonide;   Drug: Budesonide, Fluticasone, Beclomethasone;   Drug: Budesonide, Beclomethasone, Fluticasone;   Drug: Beclomethasone, Fluticasone, Budesonide;   Drug: Beclomethasone, Budesonide, Fluticasone
Outcome Measures: To show that there is a growth suppressive effect of Pulmicort Flexhaler 180 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.;   To show that there is a growth suppressive effect of Qvar 890 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.
5 Recruiting Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children
Condition: Asthma
Interventions: Drug: beclomethasone+formoterol 50/6 (1 inhalation);   Drug: CHF 1535 50/6 (2 inhalations);   Drug: CHF 1535 50/6 (4 inhalations);   Drug: Formoterol + Beclomethasone dipropionate;   Drug: Placebo (6 inhalations)
Outcome Measures: bronchodilator effect of test treatment;   dose-related effects of test treatment
6 Unknown  A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps
Condition: Nasal Polyps
Interventions: Drug: Intranasal Beclomethasone aerosol;   Drug: Intranasal Beclomethasone spray
Outcome Measures: Difference in overall quality of life as measured by the Rhinitis Quality of Life Questionnaire;   Difference in Nasal Airflow Resistance as measured an anterior rhinomanometry
7 Recruiting Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Condition: Chronic Gastrointestinal Graft vs Host Disease
Interventions: Drug: orBec;   Drug: Placebo
Outcome Measure: GI GVHD symptoms
8 Unknown  Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation
Condition: Asthma
Intervention: Device: Beclomethasone/formoterol pMDI with or without Vortex spacer
Outcome Measures: Change in Asthma Control Test Score;   Changes in Forced Expiratory Volume in the first second (FEV1)
9 Recruiting Targeted Small Airways Therapy in Persistent Asthma
Condition: Asthma
Intervention: Drug: Qvar® (beclometasone dipropionate HFA)
Outcome Measures: Change in Asthma Control Questionnaire score from post-run-in baseline;   Impulse oscillometry;   Spirometry;   Blood eosinophilic cationic protein;   Blood eosinophils;   Exhaled Nitric Oxide;   Mannitol PD15;   Overnight urinary cortisol/creatinine ratio;   Domiciliary peak expiratory flow;   Symptoms and reliever use;   Mini Asthma Quality of Life Questionnaire
10 Recruiting Efficacy of Fixed Combination of Beclomethasone + Formoterol + Glycopyrrolate Versus Foster® in Chronic Obstructive Pulmonary Diseases
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Beclometasone/Formoterol/Glycopyrrolate;   Drug: Beclometasone/Formoterol
Outcome Measures: Pre-dose and 2-hour post-dose morning FEV1 at week 26 and TDI score at week 26;   COPD exacerbation rate
11 Recruiting A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults
Condition: Pharmacokinetics
Interventions: Drug: Beclomethasone dipropionate BAI;   Drug: Beclomethasone dipropionate MDI
Outcome Measures: Area under the plasma drug concentration-time (AUC0-t);   Maximum observed plasma drug concentration (Cmax);   Area under the plasma drug concentration-time (AUC0-∞);   Time to maximum observed plasma drug concentration (tmax);   Terminal elimination half-life (t½);   Summary of Participants with Adverse Events
12 Recruiting Effect of Inhaled Steroids on Gene Expression in the Lungs - 2
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Beclomethasone
Outcome Measure: Microarray chips are scanned and the image analyzed using the Affymatrix Microarray suite algorithm. The data is normalized and differential expression is determined by fold change of the individual genes.
13 Recruiting A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
Condition: Persistent Asthma
Interventions: Drug: Beclomethasone dipropionate breath-actuated inhaler;   Drug: Placebo breath-actuated inhaler;   Drug: albuterol/salbutamol
Outcome Measures: Change from Baseline in Trough Morning Forced Expiratory Volume in 1 Second (FEV1) over the 12-week Treatment Period;   Change from Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) over the 12-week Treatment Period;   Change from Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) over the 12-week Treatment Period;   Time to Participant Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma during the 12-week Treatment Period;   Change from Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) over weeks 1-12;   Change from Baseline in the Weekly Average of Total Daily Asthma Symptom Score over Weeks 1-12
14 Recruiting Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2
Condition: Asthma
Intervention: Drug: Beclomethasone
Outcome Measures: sputum cytokine mRNA levels;   steroid-responsiveness
15 Recruiting A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 5-11 Years Old With Persistent Asthma
Condition: Asthma
Interventions: Drug: Beclomethasone dipropionate;   Drug: Placebo;   Drug: albuterol/salbutamol 90 mcg
Outcome Measures: Change from baseline in percent predicted trough morning forced expiratory volume in 1 second (FEV1) over the 12-week treatment period;   Change from baseline in weekly average of daily trough morning peak expiratory flow (PEF) over the 12-week treatment period;   Change from baseline in weekly average of daily evening peak expiratory flow (PEF) over the 12-week treatment period;   Change from baseline in the weekly average of total daily (24-hour) use of albuterol/salbutamol inhalation aerosol (number of inhalations) over weeks 1-12;   Change from baseline in the weekly average of the total daily asthma symptom score over weeks 1-12;   Time to patient withdrawal due to meeting stopping criteria for worsening asthma during the 12-week treatment period;   Change from baseline in trough morning forced expiratory volume in one second (FEV1) over the 12-week treatment period;   Change from baseline in total daily (24-hour) use of albuterol/salbutamol inhalation aerosol (number of inhalations) over the first 14 days on study treatment, over weeks 1-12 and at endpoint
16 Unknown  Beta Blocker Therapy in Mild to Moderate Asthmatics
Condition: Asthma
Interventions: Drug: Propranolol;   Drug: Placebo;   Drug: Qvar 50;   Drug: Qvar 100
Outcome Measures: Change in Histamine provocative concentration causing 20% fall in FEV1 (PC20)at 6 weeks;   Change in Impulse oscillometry parameters at 6 weeks;   Change in Spirometry parameters at 6 weeks;   Change in resting heart rate at 6 weeks;   Change in resting blood pressure at 6 weeks;   Change in exhaled tidal nitric oxide levels at 6 weeks;   Change in overnight urinary cortisol/creatinine ratio (OUCC) at 6 weeks;   Change in symptom scores (Asthma control questionnaire and Asthma quality of life questionnaire) at 6 weeks
17 Recruiting A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
Condition: Asthma
Interventions: Drug: Beclomethasone dipropionate;   Drug: Placebo;   Drug: Albuterol/salbutamol
Outcome Measures: Change from baseline in trough morning forced expiratory volume in 1 second (FEV1) over the 12-week treatment period;   Change from baseline in weekly average of daily trough morning peak expiratory flow (PEF) over the 12-week treatment period;   Change from baseline in weekly average of daily evening peak expiratory flow (PEF) over the 12-week treatment period;   Time to patient withdrawal due to meeting stopping criteria for worsening asthma during the 12-week treatment period;   Change from baseline in the weekly average of total daily (24-hour) use of albuterol/salbutamol inhalation aerosol (number of inhalations) over weeks 1-12;   Change from baseline in the weekly average of the total daily asthma symptom score over weeks 1-12
18 Recruiting Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
Condition: Mild Persistent Asthma
Interventions: Drug: Flutiform 50/5 ug (2 puffs bid) pMDI;   Drug: Fluticasone 50 ug (2puffs bid) pMDI;   Drug: Beclometasone Autohaler 50 ug (2 puffs bid)
Outcome Measures: To show non-inferiority of flutiform pMDI 50/5 µg (2 puffs bid) versus fluticasone pMDI 50 µg (2 puffs bid) based on the mean lower leg growth rates.;   To compare the safety of flutiform pMDI 50/5 µg (2 puffs bid) versus fluticasone pMDI 50 µg based on overnight urinary free cortisol (corrected for creatinine).
19 Recruiting Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: BDP/FF/GB;   Drug: Tiotropium;   Drug: BDP/FF + Tiotropium
Outcome Measures: COPD exacerbation rate;   pre-dose morning FEV1
20 Recruiting Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics.
Conditions: Respiratory Tract Diseases;   Wheezing
Interventions: Drug: Beclomethasone;   Drug: Probiotics;   Drug: Placebo
Outcome Measure: Recurrent wheezing and cytokine assay.

These studies may lead to new treatments and are adding insight into Qvar etiology and treatment.

A major focus of Qvar research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Qvar